These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
154 related items for PubMed ID: 38825890
21. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis. Liang X, Chen X, Li H, Li Y. Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447 [Abstract] [Full Text] [Related]
23. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis]. Chen K, Sun B. Zhongguo Fei Ai Za Zhi; 2020 Nov 20; 23(11):927-940. PubMed ID: 33203196 [Abstract] [Full Text] [Related]
26. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors. Qin Z, Liu K, Xu X, Li T, Ge Y, Wu B, Xing C, Mao H. Future Oncol; 2022 May 20; 18(16):1951-1962. PubMed ID: 35232231 [Abstract] [Full Text] [Related]
27. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M, Yuan Y. Medicine (Baltimore); 2018 Aug 20; 97(33):e11936. PubMed ID: 30113497 [Abstract] [Full Text] [Related]
30. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. Su Q, Zhu EC, Wu JB, Li T, Hou YL, Wang DY, Gao ZH. Front Immunol; 2019 Aug 20; 10():108. PubMed ID: 30778352 [Abstract] [Full Text] [Related]
31. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H, Nakagawa K. Int J Clin Oncol; 2020 May 20; 25(5):818-830. PubMed ID: 31549270 [Abstract] [Full Text] [Related]
33. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza MC, Piperdi B, Gadgeel SM. Cancer; 2020 Nov 15; 126(22):4867-4877. PubMed ID: 32914866 [Abstract] [Full Text] [Related]
38. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, Lu B, Wang X. Cancer Med; 2021 Feb 15; 10(4):1222-1239. PubMed ID: 33465302 [Abstract] [Full Text] [Related]
39. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Song P, Zhang D, Cui X, Zhang L. Thorac Cancer; 2020 Sep 15; 11(9):2406-2430. PubMed ID: 32643323 [Abstract] [Full Text] [Related]
40. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials. Lin LL, Lin GF, Luo Q, Chen XQ. Int Immunopharmacol; 2019 Dec 15; 77():105975. PubMed ID: 31704288 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]